Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →

This Sources Sought opportunity from Agency For International Development was posted on December 2, 2024. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Sources Sought/RFI Innovations in Malaria Vaccines and Biologics Development (IMVB)

Closed
SS-RFI-7200AA-25-IMVBFederal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

AI Contract Overview

Show more

The contract is a part of the United States Agency for International Development's (USAID) Malaria Vaccine Development Program (MVDP) and aims to support the development of malaria vaccines or monoclonal antibodies (mAbs) that combat Plasmodium falciparum infection. The initiative, known as Innovations in Malaria Vaccine and Biologics (IMVB), is focused on strategic research targeting the pre-erythrocytic and erythrocytic stages of the malaria parasite's lifecycle. This involves prototype vaccine development, preclinical trials, and early clinical studies to identify promising vaccine candidates that surpass the efficacy, durability, and affordability of current World Health Organization (WHO)-recommended options, ultimately aiming to meet the WHO’s Preferred Product Characteristics for malaria vaccines. The activity may also explore mAbs to enhance vaccine development and provide passive protection against malaria. The contract, identified by solicitation number SS-RFI-7200AA-25-IMVB, is classified under the NAICS code 541715, indicating a focus on research and development in the physical, engineering, and life sciences. The posting was made on December 2, 2024, with a response deadline set for January 3, 2025. Interested parties can reach the points of contact through emails provided, with the primary contact being via [email hidden]. The opportunity is under the oversight of the USAID M/OAA office in Washington, DC, and it is actively seeking sources to engage in the advancement of malaria vaccine technologies. Further information and resources about the contract can be accessed through the specified links to the SAM.gov portal.

General Info

USAID’s contract supports malaria vaccine and mAb development through strategic research and trials.

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Place of Performance

DC, USA

Set-Aside

NONE

Documents

1

SS-RFI-7200AA-25-IMVB: Innovations in Malaria Vaccines and Biologics Development

PDF, High priority: read this firstrfi
High

AI Contract Breakdown

Uniform Contract Format

Contract not broken down yet

CLEATUS splits the solicitation into Uniform Contract Format (UCF) sections: scope, pricing, deliverables, and evaluation criteria.

Timeline

1 update
PhaseClosed
Posted

Sources Sought

Notice updated

The notice title changed.

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Get full access to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyAgency For International Development → AGENCY FOR INTERNATIONAL DEVELOPMENT
Contacts2 people available
OfficeWASHINGTON, DC, 20523, USA
Office AddressWASHINGTON, DC, 20523, USA
Contacts

Full Description

Show more

The purpose is to support the efforts of the United States Agency for International Development (USAID) Malaria Vaccine Development Program (MVDP) to develop malaria vaccines or monoclonal antibodies (mAbs) that reduce morbidity and mortality due to malaria caused by infection with Plasmodium falciparum. The Innovations in Malaria Vaccine and Biologics (IMVB) activity is a part of the MVDP portfolio that will support strategic research of new or improved malaria vaccines that target the pre-erythrocytic and/or erythrocytic stages of the parasite life cycle that will include prototype vaccine development, preclinical studies, and/or early clinical studies of promising vaccine candidates that offer improvements in efficacy, durability, and affordability over the currently WHO-recommended vaccines, with hopes of meeting the World Health Organization’s (WHO) Preferred Product Characteristics (PPCs) for malaria vaccines. The activity may also support research on mAbs for use in development of improved malaria vaccines and passive protection against malaria.

Earlier notices in this NAICS code

Posted before this notice, open and closed

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS